348 results on '"Hoi, Alberta"'
Search Results
102. Development of the Asia Pacific Lupus Collaboration cohort
- Author
-
Kandane‐Rathnayake, Rangi, primary, Golder, Vera, additional, Louthrenoo, Worawit, additional, Luo, Shue‐Fen, additional, Jan Wu, Yeong‐Jian, additional, Li, Zhanguo, additional, An, Yuan, additional, Lateef, Aisha, additional, Sockalingam, Sargunan, additional, Navarra, Sandra V., additional, Zamora, Leonid, additional, Hamijoyo, Laniyati, additional, Katsumata, Yasuhiro, additional, Harigai, Masayoshi, additional, Chan, Madelynn, additional, O’Neill, Sean, additional, Goldblatt, Fiona, additional, Hao, Yanjie, additional, Zhang, Zhuoli, additional, Al‐Saleh, Jamal, additional, Khamashta, Munther, additional, Takeuchi, Tsutomu, additional, Tanaka, Yoshiya, additional, Bae, Sang‐Cheol, additional, Lau, Chak Sing, additional, Hoi, Alberta, additional, Nikpour, Mandana, additional, and Morand, Eric F., additional
- Published
- 2018
- Full Text
- View/download PDF
103. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
- Author
-
Vincent, Fabien B, primary, Slavin, Laura, additional, Hoi, Alberta Y, additional, Kitching, Arthur Richard, additional, Mackay, Fabienne, additional, Harris, James, additional, Kandane-Rathnayake, Rangi, additional, and Morand, Eric F, additional
- Published
- 2018
- Full Text
- View/download PDF
104. Additional file 1: Table S1. of Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
- Author
-
Golder, Vera, Rangi Kandane-Rathnayake, Hoi, Alberta, Molla Huq, Worawit Louthrenoo, An, Yuan, Li, Zhan, Shue Luo, Sargunan Sockalingam, Chak Lau, Mok, Mo, Lateef, Aisha, Franklyn, Kate, Morton, Susan, Navarra, Sandra, Zamora, Leonid, Yeong-Jian Wu, Laniyati Hamijoyo, Chan, Madelynn, OâNeill, Sean, Goldblatt, Fiona, Mandana Nikpour, and Morand, Eric
- Abstract
Disease manifestations ever present. Table S2. Comparison of SF-36 domain scores by patient and disease characteristics (DOCX 19 kb)
- Published
- 2017
- Full Text
- View/download PDF
105. The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
- Author
-
Anania, Jessica C., primary, Trist, Halina M., additional, Palmer, Catherine S., additional, Tan, Peck Szee, additional, Kouskousis, Betty P., additional, Chenoweth, Alicia M., additional, Kent, Stephen J., additional, Mackay, Graham A., additional, Hoi, Alberta, additional, Koelmeyer, Rachel, additional, Slade, Charlotte, additional, Bryant, Vanessa L., additional, Hodgkin, Philip D., additional, Aui, Pei Mun, additional, van Zelm, Menno C., additional, Wines, Bruce D., additional, and Hogarth, P. Mark, additional
- Published
- 2018
- Full Text
- View/download PDF
106. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
- Author
-
Mende, Rachel, primary, Vincent, Fabien B., additional, Kandane-Rathnayake, Rangi, additional, Koelmeyer, Rachel, additional, Lin, Emily, additional, Chang, Janet, additional, Hoi, Alberta Y., additional, Morand, Eric F., additional, Harris, James, additional, and Lang, Tali, additional
- Published
- 2018
- Full Text
- View/download PDF
107. Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis
- Author
-
Vincent, Fabien B, primary, Lin, Emily, additional, Sahhar, Joanne, additional, Ngian, Gene‐Siew, additional, Kandane‐Rathnayake, Rangi, additional, Mende, Rachel, additional, Hoi, Alberta Y, additional, Morand, Eric F, additional, Lang, Tali, additional, and Harris, James, additional
- Published
- 2018
- Full Text
- View/download PDF
108. Additional file 1: Table S1. of Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort
- Author
-
Golder, Vera, Rangi Kandane-Rathnayake, Hoi, Alberta, Molla Huq, Worawit Louthrenoo, An, Yuan, Li, Zhan, Shue Luo, Sargunan Sockalingam, Chak Lau, Lee, Alfred, Mok, Mo, Lateef, Aisha, Franklyn, Kate, Morton, Susan, Navarra, Sandra, Zamora, Leonid, Yeong-Jian Wu, Laniyati Hamijoyo, Chan, Madelynn, OâNeill, Sean, Goldblatt, Fiona, Morand, Eric, and Mandana Nikpour
- Abstract
Multiple logistic regression model properties. Table S2. Effect of disease manifestations and damage at recruitment on LLDAS components. (DOCX 59Â kb)
- Published
- 2016
- Full Text
- View/download PDF
109. Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?
- Author
-
Boulos, Daniel, primary, Koelmeyer, Rachel L, additional, Morand, Eric F, additional, and Hoi, Alberta Y, additional
- Published
- 2017
- Full Text
- View/download PDF
110. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study
- Author
-
Golder, Vera, primary, Huq, Molla, additional, Franklyn, Kate, additional, Calderone, Alicia, additional, Lateef, Aisha, additional, Lau, Chak Sing, additional, Lee, Alfred Lok Hang, additional, Navarra, Sandra Teresa V., additional, Godfrey, Timothy, additional, Oon, Shereen, additional, Hoi, Alberta Yik Bun, additional, Morand, Eric Francis, additional, and Nikpour, Mandana, additional
- Published
- 2017
- Full Text
- View/download PDF
111. Systemic lupus erythematosus: an update
- Author
-
Golder, Vera, primary and Hoi, Alberta, additional
- Published
- 2017
- Full Text
- View/download PDF
112. The Australian Lupus Registry and Biobank: a timely initiative
- Author
-
O'Neill, Sean, primary, Morand, Eric F, additional, and Hoi, Alberta, additional
- Published
- 2017
- Full Text
- View/download PDF
113. Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap
- Author
-
Golder, Vera, primary, Morand, Eric F., additional, and Hoi, Alberta Y., additional
- Published
- 2017
- Full Text
- View/download PDF
114. Independent association of glucocorticoids with damage accrual in SLE
- Author
-
Apostolopoulos, Diane, primary, Kandane-Rathnayake, Rangi, additional, Raghunath, Sudha, additional, Hoi, Alberta, additional, Nikpour, Mandana, additional, and Morand, Eric F, additional
- Published
- 2016
- Full Text
- View/download PDF
115. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus
- Author
-
Godsell, Jack, primary, Rudloff, Ina, additional, Kandane-Rathnayake, Rangi, additional, Hoi, Alberta, additional, Nold, Marcel F., additional, Morand, Eric F., additional, and Harris, James, additional
- Published
- 2016
- Full Text
- View/download PDF
116. The art of managing medical uncertainty
- Author
-
Johnson, Paul, primary and Hoi, Alberta, additional
- Published
- 2016
- Full Text
- View/download PDF
117. Trimethoprim‐induced aseptic meningitis: a reminder case review
- Author
-
Mathanasenarajah, Gayathiri, primary and Hoi, Alberta, additional
- Published
- 2015
- Full Text
- View/download PDF
118. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
- Author
-
Franklyn, Kate, primary, Lau, Chak Sing, additional, Navarra, Sandra V, additional, Louthrenoo, Worawit, additional, Lateef, Aisha, additional, Hamijoyo, Laniyati, additional, Wahono, C Singgih, additional, Chen, Shun Le, additional, Jin, Ou, additional, Morton, Susan, additional, Hoi, Alberta, additional, Huq, Molla, additional, Nikpour, Mandana, additional, and Morand, Eric F, additional
- Published
- 2015
- Full Text
- View/download PDF
119. Analysis of Serum Interleukin (IL)-iβ and IL-18 in Systemic Lupus Erythematosus.
- Author
-
Mende, Rachel, Vincent, Fabien B., Kandane-Rathnayake, Rangi, Koelmeyer, Rachel, Lin, Emily, Janet Chang, Hoi, Alberta Y., Morand, Eric F., Harris, James, and Tali Lang
- Subjects
SYSTEMIC lupus erythematosus ,INTERLEUKIN-1 ,INTERLEUKIN-18 - Abstract
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by biological and clinical heterogeneity. The interleukin (IL)-1 superfamily is a group of innate cytokines that contribute to pathogenesis in many autoimmune diseases. IL-1β and IL-18 are two members that have been shown to play a role in murine lupus-like models, but their role in human SLE remains poorly understood. Here, IL-1β and IL-18 were quantified by enzyme-linked immunosorbent assay in the serum of healthy controls (HCs) and SLE patients from a prospectively followed cohort. Disease activity and organ damage were assessed using SLE disease activity index 2000 (SLEDAI-2K) and SLE damage index scores (SDI), respectively. 184 SLE patients (mean age 44.9 years, 91% female, 56% double-stranded deoxyribonucleic acid positive) were compared to 52 HC. SLE patients had median [IQR] SLEDAI-2K of 4 [2,6], and SDI of 1 [0-2]. Serum IL-18 levels were statistically significantly higher in SLE patients compared to HCs. Univariable linear regression analyses showed that patients with active renal disease or irreversible organ damage had statistically significantly elevated serum IL-18 levels. The association between serum IL-18 and active renal disease was confirmed in multivariable analysis after adjusting for ethnicity and organ damage. High baseline serum IL-18 levels were associated with organ damage at the subsequent visit. Serum IL-1β levels were not significantly elevated in SLE patients when compared to HCs and had no association with overall or organ-specific disease activity or organ damage in cross-sectional and longitudinal analyses. Our data suggest that serum IL-18 and IL-1β have different clinical implications in SLE, with IL-18 being potentially associated with active renal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
120. Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
- Author
-
Croyle, Lucy, primary, Hoi, Alberta, additional, and Morand, Eric F, additional
- Published
- 2015
- Full Text
- View/download PDF
121. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.
- Author
-
Golder, Vera, Kandane-Rathnayake, Rangi, Yik-Bun Hoi, Alberta, Huq, Molla, Louthrenoo, Worawit, Yuan An, Zhan Guo Li, Shue Fen Luo, Sockalingam, Sargunan, Chak Sing Lau, Mo Yin Mok, Lateef, Aisha, Franklyn, Kate, Morton, Susan, Navarra, Sandra Teresa V., Zamora, Leonid, Yeong-Jian Wu, Hamijoyo, Laniyati, Chan, Madelynn, and O'Neill, Sean
- Published
- 2017
- Full Text
- View/download PDF
122. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
- Author
-
Golder, Vera, Kandane-Rathnayake, Rangi, Hoi, Alberta Yik-Bun, Huq, Molla, Louthrenoo, Worawit, Yuan An, Zhan Guo Li, Shue Fen Luo, Sockalingam, Sargunan, Chak Sing Lau, Lee, Alfred Lok, Mo Yin Mok, Lateef, Aisha, Franklyn, Kate, Morton, Susan, Navarra, Sandra Teresa V., Zamora, Leonid, Yeong-Jian Wu, Hamijoyo, Laniyati, and Madelynn Chan
- Published
- 2016
- Full Text
- View/download PDF
123. The need to define treatment goals for systemic lupus erythematosus
- Author
-
Franklyn, Kate, primary, Hoi, Alberta, additional, Nikpour, Mandana, additional, and Morand, Eric F., additional
- Published
- 2014
- Full Text
- View/download PDF
124. Is there still a role for abatacept in the treatment of lupus?
- Author
-
Hoi, Alberta, primary and Littlejohn, Geoff, additional
- Published
- 2014
- Full Text
- View/download PDF
125. Clinical associations of serum interleukin-17 in systemic lupus erythematosus
- Author
-
Vincent, Fabien B, primary, Northcott, Melissa, additional, Hoi, Alberta, additional, Mackay, Fabienne, additional, and Morand, Eric F, additional
- Published
- 2013
- Full Text
- View/download PDF
126. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
- Author
-
Franklyn, Kate, Chak Sing Lau, Navarra, Sandra V., Louthrenoo, Worawit, Lateef, Aisha, Hamijoyo, Laniyati, Wahono, C. Singgih, Shun Le Chen, Ou Jin, Morton, Susan, Hoi, Alberta, Huq, Molla, Nikpour, Mandana, Morand, Eric F., Lau, Chak Sing, Chen, Shun Le, Jin, Ou, and Asia-Pacific Lupus Collaboration
- Subjects
SYSTEMIC lupus erythematosus diagnosis ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH evaluation ,RISK assessment ,SYSTEMIC lupus erythematosus ,TIME ,EVALUATION research ,RELATIVE medical risk ,SEVERITY of illness index - Abstract
Aims: Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low Disease Activity State (LLDAS).Methods: A consensus definition of LLDAS was generated using Delphi and nominal group techniques. Criterion validity was determined by measuring the ability of LLDAS attainment, in a single-centre SLE cohort, to predict non-accrual of irreversible organ damage, measured using the Systemic Lupus International Collaborating Clinics Damage Index (SDI).Results: Consensus methodology led to the following definition of LLDAS: (1) SLE Disease Activity Index (SLEDAI)-2K ≤4, with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) and no haemolytic anaemia or gastrointestinal activity; (2) no new lupus disease activity compared with the previous assessment; (3) a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI physician global assessment (scale 0-3) ≤1; (4) a current prednisolone (or equivalent) dose ≤7.5 mg daily; and (5) well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents. Achievement of LLDAS was determined in 191 patients followed for a mean of 3.9 years. Patients who spent greater than 50% of their observed time in LLDAS had significantly reduced organ damage accrual compared with patients who spent less than 50% of their time in LLDAS (p=0.0007) and were significantly less likely to have an increase in SDI of ≥1 (relative risk 0.47, 95% CI 0.28 to 0.79, p=0.005).Conclusions: A definition of LLDAS has been generated, and preliminary validation demonstrates its attainment to be associated with improved outcomes in SLE. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
127. Abatacept in the treatment of lupus
- Author
-
Hoi, Alberta Y., primary and Littlejohn, Geoffrey O., additional
- Published
- 2012
- Full Text
- View/download PDF
128. Macrophage Migration Inhibitory Factor: A Therapeutic Target Across Inflammatory Diseases
- Author
-
Hoi, Alberta, primary, Iskander, Magdy, additional, and Morand, Eric, additional
- Published
- 2007
- Full Text
- View/download PDF
129. Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/lpr Mice
- Author
-
Hoi, Alberta Y., primary, Hickey, Michael J., additional, Hall, Pamela, additional, Yamana, Jiro, additional, O’Sullivan, Kim M., additional, Santos, Leilani L., additional, James, Will G., additional, Kitching, A. Richard, additional, and Morand, Eric F., additional
- Published
- 2006
- Full Text
- View/download PDF
130. Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention.
- Author
-
Tina Ko, Ai Li Yeo, Sarah Luu, Dendle, Claire, Woolley, Ian, Morand, Eric, and Hoi, Alberta
- Subjects
DIAGNOSIS ,SYSTEMIC lupus erythematosus ,BACTERIAL meningitis - Abstract
Letter to the Editor Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention Sir, Loss of splenic function is associated with increased rates of sepsis and thrombosis, with consequent increases in morbidity and mortality. 7 The lupus clinic is held in Monash Medical Centre, Clayton a tertiary referral centre, and is the largest lupusspecific clinic in Australia. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
131. Systemic lupus erythmatosus - When to consider and management options.
- Author
-
Apostolopoulos, Diane and Hoi, Alberta Yik-Bun
- Published
- 2013
132. Is there still a role for abataceptin the treatment of lupus?
- Author
-
Hoi, Alberta and Littlejohn, Geoff
- Abstract
Introduction:The quest for safer and more effective treatments for systemic lupus erythematosus (SLE) has led to the development of many new biologic therapies. Abataceptis the first drug targeting co-stimulation between T cells and antigen presenting cells, with abundant pre-clinical evidence to support its use in SLE.Areas covered:This review will present the relevant aspects of lupus pathophysiology pertaining to the mechanism of action of abatacept, a summary of murine studies and the latest human clinical trials.Expert opinion:Abatacept has demonstrated efficacy in both rheumatoid arthritis and psoriatic arthritis, and earlier studies have suggested tantalising evidence of efficacy in SLE. However, the latest randomised double-blinded study showed disappointingly negative results, much like the case of rituximab in SLE. Currently, abatacept remains a possible therapeutic option as an off-label therapy, and it is a part of our therapeutic armamentarium in difficult cases. The need to find appropriate definitions of response and optimal study design continues to be paramount in the field of lupus therapies.
- Published
- 2014
- Full Text
- View/download PDF
133. Pregnancy outcomes in Australian patients with systemic lupus erythematosus.
- Author
-
Isojima, Sakiko, Li, Ning, Rowson, Saskia, Kandane‐Rahtnayake, Rangi, Koelmeyer, Rachel, Morand, Eric F., and Hoi, Alberta
- Subjects
- *
FETAL growth retardation , *PREGNANCY outcomes , *MEDICAL specialties & specialists , *REPRODUCTIVE history , *LOGISTIC regression analysis - Abstract
Background Aims Methods Results Conclusion Systemic lupus erythematosus (SLE) affects women, with the onset of disease typically around the childbearing years.This study examines the frequency and risk factors for adverse pregnancy outcomes (APOs) in an Australian cohort, and any disease flares during pregnancy and post partum.Female patients with SLE enrolled in the Australian Lupus Registry and Biobank (ALRB) between January 2007 and June 2019 were studied. Self‐reported pregnancy history, including adverse foetal or maternal outcomes, was collected at the time of enrolment and updated as appropriate. Baseline demographics, clinical parameters, medication exposure and disease activity were collected. Factors associated with APO were examined using univariate and multivariate logistic regression analyses.Pregnancy history was available in 278 patients; 30% were nulliparous. Most pregnancies occurred before the diagnosis of SLE. Patients who had pregnancies after SLE diagnosis had an earlier age of diagnosis, and had fewer pregnancies. The APO rate was 44.3% in the overall cohort, with most presenting as prematurity with or without foetal growth restriction. Women with APO were also diagnosed with SLE at a younger age and had a higher prevalence of anti‐cardiolipin antibodies and hypocomplementemia. Early age of SLE diagnosis was a significant independent risk factor for APO. No increase in disease flare was observed in those who experienced APO during the observation period of ALRB.This study shows a considerable incidence of APO in patients with SLE, emphasising the need for pre‐pregnancy counselling and collaboration between maternal‐foetal medicine specialists and rheumatologists, especially for women diagnosed with SLE at a younger age. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
134. Abataceptin the treatment of lupus
- Author
-
Hoi, Alberta Y. and Littlejohn, Geoffrey O.
- Abstract
Introduction:In contrast to other areas in rheumatology, the therapeutic armamentarium in systemic lupus erythematosus (SLE) has lagged behind due to a number of reasons. While SLE is the prototypical multi-system autoimmune disease, its low incidence and the heterogeneity in its clinical manifestations have made it difficult to study. Despite advances in the understanding and application of immunology, the emergence of new targets has not been successfully validated largely due to the difficult-to-use outcome measures. Among the many targets studied, co-stimulation blockade that prevents activation of T cells by antigen-presenting cells, poses an interesting concept that is plausible based on basic science, animal and early human studies.Areas covered:The authors hereby review the development of abataceptin the treatment of SLE and possible future directions.Expert opinion:Despite failure to achieve primary efficacy end points, the studies of abatacept in lupus provided tantalising evidence that co-stimulatory blockade is a feasible option worthy of further exploration.
- Published
- 2012
- Full Text
- View/download PDF
135. Disease course following High Disease Activity Status revealed patterns in SLE
- Author
-
Hoi, Alberta, Koelmeyer, Rachel, Bonin, Julie, Sun, Ying, Kao, Amy, Gunther, Oliver, Nim, Hieu T., and Morand, Eric
- Abstract
Background: We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this. Methods: All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual. Results: Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08–2.97, p= 0.02, and OR 3.31, 95% CI 1.66–13.26, p= 0.01, respectively). Conclusion: HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients.
- Published
- 2021
- Full Text
- View/download PDF
136. Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus.
- Author
-
Figgett, William A, Monaghan, Katherine, Ng, Milica, Alhamdoosh, Monther, Maraskovsky, Eugene, Wilson, Nicholas J, Hoi, Alberta Y, Morand, Eric F, and Mackay, Fabienne
- Subjects
MACHINE learning ,GENE expression profiling ,EXPERIMENTAL design ,AUTOIMMUNE diseases ,SYSTEMIC lupus erythematosus - Abstract
Objectives: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that is difficult to treat. There is currently no optimal stratification of patients with SLE, and thus, responses to available treatments are unpredictable. Here, we developed a new stratification scheme for patients with SLE, based on the computational analysis of patients' whole‐blood transcriptomes. Methods: We applied machine learning approaches to RNA‐sequencing (RNA‐seq) data sets to stratify patients with SLE into four distinct clusters based on their gene expression profiles. A meta‐analysis on three recently published whole‐blood RNA‐seq data sets was carried out, and an additional similar data set of 30 patients with SLE and 29 healthy donors was incorporated in this study; a total of 161 patients with SLE and 57 healthy donors were analysed. Results: Examination of SLE clusters, as opposed to unstratified SLE patients, revealed underappreciated differences in the pattern of expression of disease‐related genes relative to clinical presentation. Moreover, gene signatures correlated with flare activity were successfully identified. Conclusion: Given that SLE disease heterogeneity is a key challenge hindering the design of optimal clinical trials and the adequate management of patients, our approach opens a new possible avenue addressing this limitation via a greater understanding of SLE heterogeneity in humans. Stratification of patients based on gene expression signatures may be a valuable strategy allowing the identification of separate molecular mechanisms underpinning disease in SLE. Further, this approach may have a use in understanding the variability in responsiveness to therapeutics, thereby improving the design of clinical trials and advancing personalised therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
137. Enrolment of the first paediatric cohort into the Australian lupus registry and biobank: A single-centre experience.
- Author
-
Power, Bronwyn D, Kandane-Rathnayake, Rangi, Tiller, Georgina, Renton, William D, Cox, Angela, Johnstone, Lilian, Hoi, Alberta, and Gowdie, Peter
- Subjects
- *
LUPUS nephritis , *PEDIATRIC rheumatology , *SYSTEMIC lupus erythematosus , *PEDIATRICS , *QUALITY of life , *AUSTRALIANS - Abstract
Introduction: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures. Methods: All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified. Patients were enrolled in the ALRB if they met ≥4/11 of the American College of Rheumatology (ACR) 1997 SLE classification criteria or the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria. Enrolment data including demographics, clinical characteristics, serological profiles, disease activity and damage assessments were recorded. Peds-QL Rheumatology and General Modules were used to assess patient and parent-reported outcomes. Results: Twenty-seven patients were eligible for inclusion, with 26 patients (96%) consenting for enrolment. Twenty-five patients (92%) consented for biobanking. Twenty patients (77%) were female. The median age at enrolment was 16 years (interquartile range (IQR) 13.7, 17.4). The median disease duration from diagnosis was 3.2 years (IQR 1.4, 5.3). Sixteen patients (62%) had synovitis, 16 (62%) had cutaneous involvement, 4 (15%) had serositis, 17 (65%) had haematological involvement and 7 (27%) had renal involvement at enrolment. Nineteen patients (73%) were prescribed at least two disease-modifying anti-rheumatic medications (DMARDs). Hydroxychloroquine (n = 22, 85%) and mycophenolate mofetil (n = 9, 35%) were the most commonly prescribed DMARDs. The median SLEDAI-2K score was 2 (IQR 2, 4). Six patients (23%) had active disease (SLEDAI-2K ≥6) at enrolment. Three patients (11.5%) had reported damage using the SLICC/ACR Damage Index. Twenty-three children (88%) and eighteen parents (69%) completed the Paediatric Quality of Life Inventory. Quality of life scores reported across domains of physical, emotional, social and school functioning at enrolment were comparable to previously studied paediatric cohorts with SLE and other chronic diseases. Conclusion: We have established our centre as the first paediatric participating site of the ALRB, providing contemporary data on the clinical characteristics, serological profile and health-related quality of life outcomes of Australian children with SLE. Paediatric involvement with this national registry will provide a unique perspective for future clinical and scientific research. Collection of Australian-specific paediatric longitudinal data will also enable a broader understanding of SLE within a multicultural Australian population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
138. Trimethoprim-induced aseptic meningitis: a reminder case review.
- Author
-
Mathanasenarajah, Gayathiri and Hoi, Alberta
- Subjects
- *
TRIMETHOPRIM , *MENINGITIS - Published
- 2017
- Full Text
- View/download PDF
139. Regulatory T Cells in SLE
- Author
-
Cheong, Rachel, Ooi, Joshua, and Hoi, Alberta, editor
- Published
- 2021
- Full Text
- View/download PDF
140. B Cell-Targeted Therapies in Systemic Lupus Erythematosus
- Author
-
Vincent, Fabien B., Figgett, William A., Hibbs, Margaret L., and Hoi, Alberta, editor
- Published
- 2021
- Full Text
- View/download PDF
141. Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus
- Author
-
Oon, Shereen and Hoi, Alberta, editor
- Published
- 2021
- Full Text
- View/download PDF
142. Hallmark of Systemic Lupus Erythematosus: Role of B Cell Hyperactivity
- Author
-
Vincent, Fabien B., Figgett, William A., Hibbs, Margaret L., and Hoi, Alberta, editor
- Published
- 2021
- Full Text
- View/download PDF
143. Balancing Strategies: GC and GILZ Axis
- Author
-
Nataraja, Champa, Zhu, Wendy, Dankers, Wendy, Jones, Sarah A., and Hoi, Alberta, editor
- Published
- 2021
- Full Text
- View/download PDF
144. Global epidemiology of systemic lupus erythematosus.
- Author
-
Barber, Megan R. W., Drenkard, Cristina, Falasinnu, Titilola, Hoi, Alberta, Mak, Anselm, Kow, Nien Yee, Svenungsson, Elisabet, Peterson, Jonna, Clarke, Ann E., and Ramsey-Goldman, Rosalind
- Subjects
- *
SYSTEMIC lupus erythematosus , *CARDIOVASCULAR diseases , *EPIDEMIOLOGY , *DEATH rate , *GLOBAL burden of disease , *SOCIOECONOMIC status , *WORLD health , *DISEASE incidence , *DISEASE prevalence - Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations that predominantly affects young women. Certain ethnic groups are more vulnerable than others to developing SLE and experience increased morbidity and mortality. Reports of the global incidence and prevalence of SLE vary widely, owing to inherent variation in population demographics, environmental exposures and socioeconomic factors. Differences in study design and case definitions also contribute to inconsistent reporting. Very little is known about the incidence of SLE in Africa and Australasia. Identifying and remediating such gaps in epidemiology is critical to understanding the global burden of SLE and improving patient outcomes. Mortality from SLE is still two to three times higher than that of the general population. Internationally, the frequent causes of death for patients with SLE include infection and cardiovascular disease. Even without new therapies, mortality can potentially be mitigated with enhanced quality of care. This Review focuses primarily on the past 5 years of global epidemiological studies and discusses the regional incidence and prevalence of SLE and top causes of mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
145. The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.
- Author
-
Liao K, Li N, Bonin J, Koelmeyer R, Kent J, Pellicano R, De Silva T, Yap K, Golder V, Kitching AR, Morand EF, and Hoi A
- Abstract
Objectives: Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjogren's disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterised., Methods: Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K ≥10, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied., Results: Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10-2.48, p= 0.015), AMS > 4 (OR 1.84, 1.18-2.88, p= 0.007), and more frequent use of glucocorticoids (OR 1.87, 1.16-3.03, p= 0.011) and immunosuppressants (OR 2.0, 1.26-3.17, p= 0.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia, and sicca symptoms were significantly linked to Ro positivity., Conclusion: Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60/Ro52 testing in the clinical evaluation of SLE., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
146. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
- Author
-
Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, Oon S, O'Neill S, Ng K, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Hoi A, Nikpour M, and Morand EF
- Subjects
- Humans, Female, Adult, Male, Prospective Studies, Middle Aged, Longitudinal Studies, Remission Induction, Quality of Life, Lupus Erythematosus, Systemic, Severity of Illness Index
- Abstract
Background: Validation of protective associations of the lupus low disease activity state (LLDAS) against flare, irreversible damage, health-related quality of life, and mortality has enabled the adoption of treat-to-target strategies in patients with systemic lupus erythematosus (SLE). Previous validation studies were of short duration, limiting the ability to detect longer term signals in flare rate and irreversible damage. In addition, previous studies have focused on percent time at target, rather than actual periods of time that are more useful in clinical practice and trials. We assessed long-term protective associations of LLDAS and remission, and specifically examined protective thresholds of sustained LLDAS and remission., Methods: Patients aged 18 years or older with SLE were followed up from May 1, 2013, to Dec 31, 2020 in a prospective, multinational, longitudinal cohort study. Patients were recruited from 25 centres in 12 countries. Multi-failure time-to-event analyses were used to assess the effect of sustained LLDAS on irreversible damage accrual (primary outcome; measured with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) and flare (key secondary outcome; measured with the SELENA Flare Index), with dose exposure and threshold effects studied. Sustained LLDAS or remission were defined as two or more consecutive visits over at least 3 months in the respective state. This study is registered with ClinicalTrials.gov, NCT03138941., Findings: 3449 patients were followed up for a median of 2·8 years (IQR 1·1-5·6), totalling 37 662 visits. 3180 (92·2%) patients were women, and 3031 (87·9%) were of Asian ethnicity. 2506 (72·7%) patients had sustained LLDAS at least once. Any duration of sustained LLDAS or remission longer than 3 months was associated with reduced damage accrual (LLDAS: hazard ratio 0·60 [95% CI 0·51-0·71], p<0·0001; remission: 0·66 [0·57-0·76], p<0·0001) and flare (LLDAS: 0·56 [0·51-0·63], p<0·0001; remission: 0·66 [0·60-0·73], p<0·0001), and increasing durations of sustained LLDAS corresponded to increased protective associations. Sustained DORIS remission or steroid-free remission were less attainable than LLDAS., Interpretation: We observed significant protective associations of LLDAS and remission against damage accrual and flare, establish a threshold of 3 months sustained LLDAS or remission as protective, and demonstrate deepening protection with longer durations of sustained LLDAS or remission., Funding: The Asia Pacific Lupus Collaboration receives project support grants from AstraZeneca, Bristol Myers Squibb, EMD Sereno, GSK, Janssen, Eli Lilly, and UCB., Competing Interests: Declaration of interests RK-R received grants from GSK and Novartis. SVN received consulting fees from Biogen, Boehringer Ingelheim, Astra Zeneca, Idorsia; payment for lectures from AstraZeneca, Boehringer Ingelheim, GSK, and Roche; participation in advisory board for Biogen; and leadership of societies, unpaid (CEO of Rheumatology Educational Trust Foundation, and Head of the SLE Special Interest Group at the Philippine Rheumatology Association). ZL received consulting fees from Pfizer, Roche, Janssen, Abbott, AbbVie, Bristol Myers Squibb, MSD, Celgene, Eli Lilly, GSK, Novartis, and UCB, and has royalties with Pfizer, Roche, Janssen, Abbott, AbbVie, Bristol Myers Squibb, MSD, Celgene, Eli Lilly, GSK, Novartis, and UCB. SS received consulting fees from Pfizer, AstraZeneca, and ZP Therapeutics. YK received payment or honoraria from GlaxoSmithKline, AstraZeneca, Sanofi, Pfizer Japan, Janssen Pharmaceutical, Chugai Pharmaceutical, Asahi Kasei Pharma, Astellas Pharma, and Mitsubishi Tanabe Pharma Corporation. MH received institutional research grants from GSK and Novartis; and honoraria for lectures from AstraZeneca and Astellas Pharma. ZZ received payment or honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Novartis, Pfizer, Roche, Sanofi, Janssen, and UCB; and participation in advisory board for Beigene. JK received speaker fees from GSK and Asahi Kasei. TT received grants from Astellas, Asahi Kasei, Chugai, and Mitsubishi Tanabe, and consulting fees from Astellas and Chugai. FG is Director of the Board of the Australian Rheumatology Association. KN received Advisory Board participation fees from AbbVie. YT received research grants from Boehringer Ingelheim, Taisho, and Chugai; and speaker fees or honoraria from AbbVie, Eisai, Chugai, Eli Lilly, Boehringer Ingelheim, GSK, Taisho, AstraZeneca, Daiichi-Sankyo, Gilead, Pfizer, UCB, Asahi-kasei, and Astellas. AH received a research grant from AstraZeneca; consulting fees from EUSA Pharma (UK); and speaker fees or honoraria from Limbic, Novartis, Moose Republic, AbbVie, and Eli Lilly. MN received an Investigator Grant from the National Health and Medical Research Council of Australia (NHMRC GNT1176538); research grants from Janssen and Boehringer Ingelheim; consulting fees from AstraZeneca and GSK; honoraria for presentations from AstraZeneca, GSK, and Boehringer Ingelheim; and support for conference attendance from Boehringer Ingelheim. EFM received consulting fees from AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, Genetech, Janssen, Novartis, Servier, and EMD Serono. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
147. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
- Author
-
Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Hoi A, and Morand EF
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Longitudinal Studies, Disease Progression, Glucocorticoids therapeutic use, Prospective Studies, Young Adult, Lupus Erythematosus, Systemic diagnosis, Severity of Illness Index
- Abstract
Objective: To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favorable outcomes in patients with recent onset systemic lupus erythematosus (SLE)., Methods: Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception cohort was defined based on disease duration < 1 year at enrollment. Patient characteristics between inception and noninception cohorts were compared. Survival analyses were performed to examine the association between LLDAS attainment and damage accrual and flare., Results: Of the total 4106 patients, 680 (16.6%) were recruited within 1 year of SLE diagnosis (inception cohort). Compared to the noninception cohort, inception cohort patients were significantly younger, had higher disease activity, and used more glucocorticoids, but had less organ damage at enrollment. Significantly fewer inception cohort patients were in LLDAS at enrollment than the noninception cohort (29.6% vs 52.3%, P < 0.001), but three-quarters of both groups achieved LLDAS at least once during follow-up. Limiting analysis only to patients not in LLDAS at enrollment, inception cohort patients were 60% more likely to attain LLDAS (hazard ratio 1.37, 95% CI 1.16-1.61, P < 0.001) than noninception cohort patients and attained LLDAS significantly faster. LLDAS attainment was significantly protective against flare in both the inception and noninception cohorts. A total of 88 (13.6%) inception cohort patients accrued organ damage during a median 2.2 years of follow-up., Conclusion: LLDAS attainment is protective from flare in recent onset SLE. Significant protection from damage accrual was not observed because of low rates of damage accrual in the first years after SLE diagnosis. (ClinicalTrials.gov: NCT03138941)., (Copyright © 2024 by the Journal of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
148. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
- Author
-
Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, Golder V, Lau CS, Lateef A, Chen YH, Luo SF, Wu YJ, Hamijoyo L, Li Z, Sockalingam S, Navarra S, Zamora L, Hao Y, Zhang Z, Chan M, Oon S, Ng K, Kikuchi J, Takeuchi T, Goldblatt F, O'Neill S, Tugnet N, Law AHN, Bae SC, Tanaka Y, Ohkubo N, Kumar S, Kandane-Rathnayake R, Nikpour M, and Morand EF
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Drug Tapering methods, Longitudinal Studies, Disease Progression, Cohort Studies, Proportional Hazards Models, Prospective Studies, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic complications, Glucocorticoids administration & dosage, Glucocorticoids therapeutic use, Prednisolone administration & dosage, Prednisolone therapeutic use, Symptom Flare Up
- Abstract
Objectives: To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE)., Methods: Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ defined as the state with serological activity (increased anti-dsDNA and/or hypocomplementemia) but without clinical activity, treated with ≤7.5 mg/day of prednisolone-equivalent GCs and not-considering duration, were studied. The risk of subsequent flare or damage accrual per 1 mg decrease of prednisolone was assessed using Cox proportional hazard models while adjusting for confounders. Observation periods were 2 years and censored if each event occurred., Results: Data from 1850 mSACQ patients were analysed: 742, 271 and 180 patients experienced overall flare, severe flare and damage accrual, respectively. Tapering GCs by 1 mg/day of prednisolone was not associated with increased risk of overall or severe flare: adjusted HRs 1.02 (95% CI, 0.99 to 1.05) and 0.98 (95% CI, 0.96 to 1.004), respectively. Antimalarial use was associated with decreased flare risk. Tapering GCs was associated with decreased risk of damage accrual (adjusted HR 0.96, 95% CI, 0.93 to 0.99) in the patients whose initial prednisolone dosages were >5 mg/day., Conclusions: In mSACQ patients, tapering GCs was not associated with increased flare risk. Antimalarial use was associated with decreased flare risk. Tapering GCs protected mSACQ patients treated with >5 mg/day of prednisolone against damage accrual. These findings suggest that cautious GC tapering is feasible and can reduce GC use in mSACQ patients., Competing Interests: Competing interests: YK received honoraria from Asahi Kasei Pharma, Astellas Pharma, AstraZeneca K.K., Chugai Pharmaceutical, GlaxoSmithKline KK, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan, Sanofi KK. EI received honoraria from Bristol-Myers Squibb KK, Eisai and consulting fees from Nippontect Systems. MH received honoraria from AbbVie GK, Ayumi Pharmaceutical, Bristol-Myers Squibb K.K., Chugai Pharmaceutical, Eisai, Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical, Nippon Boehringer Ingelheim, Pfizer Japan, Takeda Pharmaceutical, Teijin Pharma, consulting fees from AbbVie GK, Bristol-Myers Squibb K.K., Kissei Pharmaceutical, Nippon Boehringer Ingelheim, Teijin Pharma, grant/research support from AbbVie GK, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Bristol-Myers Squibb K.K., Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Sekisui Medical, Shionogi, Taisho Pharmaceutical, Takeda Pharmaceutical, Teijin Pharma. AH received honoraria from UCB, Janssen, Sandoz, Eli Lilly, consulting fees from AbbVie, GSK and grant/research support from AstraZeneca, GSK, Bristol Myers Squibb, Janssen, Merck Serono. CSL received honoraria from AstraZeneca UK and consulting fee from AstraZeneca Pharmaceuticals LP. ZL received honoraria from Pfizer, Roche, Janssen, Abbott, AbbVie, Bristol Myers Squibb, MSD, Celgene, Eli Lilly, GSK, Novartis, UCB Pharma and consulting fees from Pfizer, Roche, Janssen, Abbott, AbbVie, Bristol Myers Squibb, MSD, Celgene, Eli Lilly, GSK, Novartis, UCB Pharma. SS received consulting fees from Pfizer, AstraZeneca, ZP Therapeutics and grant/research support from Pfizer, AstraZeneca, ZP Therapeutics. SVN received consulting fees from Biogen, Boehringer Ingelheim, AstraZeneca, grant/research support from Jannsen, Novartis, Pfizer, GSK and support for attending meetings from Biogen. SOon received royalty from Venetoclax. KN is on the advisory board for AbbVie. TT received honoraria from AbbVie GK, Chugai Pharmaceutical, Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma, consulting fees from AbbVie GK, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma and grant/research support from AbbVie GK, Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma. YT received honoraria from AbbVie GK, Asahi Kasei Pharma, AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical, Eisai, Eli Lilly Japan K.K., Gilead Sciences, GlaxoSmithKline K.K., Nippon Boehringer Ingelheim, Pfizer Japan, Taiho Pharmaceutical, Taisho Pharmaceutical and grant/research support from Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical. MN received honoraria from Actelion, GSK, Janssen, Pfizer, UCB, consulting fees from Boehringer Ingelheim, Certa Therapeutics, Eli Lilly, GSK, Janssen, Pfizer, UCB and grant/research support from Actelion, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, UCB. EFM received honoraria from AstraZeneca, EMD Serono, Gilead, consulting fees from AstraZeneca, Bristol Myers Squibb, Biogen, Eli Lilly, EMD Serono, Novartis and grant/research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Biogen, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, UCB. All other authors declare no competing interests., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2024
- Full Text
- View/download PDF
149. Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care.
- Author
-
Eades LE, Hoi AY, Liddle R, Sines J, Kandane-Rathnayake R, Khetan S, Nossent J, Lindenmayer G, Morand EF, Liew DFL, Rischmueller M, Brady S, Brown A, and Vincent FB
- Abstract
The first inhabitants of Australia and the traditional owners of Australian lands are the Aboriginal and Torres Strait Islander peoples. Aboriginal and Torres Strait Islander peoples are two to four times more likely to have systemic lupus erythematosus (SLE) than the general Australian population. Phenotypically, SLE appears distinctive in Aboriginal and Torres Strait Islander peoples and its severity is substantially increased, with mortality rates up to six times higher than in the general Australian population with SLE. In particular, Aboriginal and Torres Strait Islander peoples with SLE have increased prevalence of lupus nephritis and increased rates of progression to end-stage kidney disease. The reasons for the increased prevalence and severity of SLE in this population are unclear, but socioeconomic, environmental, and biological factors are all likely to be implicated, although there are no published studies investigating these factors in Aboriginal and Torres Strait Islander peoples with SLE specifically, indicating an important knowledge gap. In this Review, we summarise the data on the incidence, prevalence, and clinical and biological findings relating to SLE in Aboriginal and Torres Strait Islander peoples and explore potential factors contributing to its increased prevalence and severity in this population. Importantly, we identify health disparities and deficiencies in health-care provision that limit optimal care and outcomes for many Aboriginal and Torres Strait Islander peoples with SLE and highlight potentially addressable goals to improve outcomes., Competing Interests: Declaration of interests FBV has received support from Janssen-Cilag and CSL for projects described in the scope of this Review and from Pfizer, Lupus Research Alliance, and SomaLogic for conference or meeting sponsorship. SK has received support from Pfizer for conference sponsorship. AYH has received support from Arthritis Australia, Perpetual IMPACT fund, AstraZeneca, Bristol Myers Squibb, Merck Serono, GSK, Eli Lilly, Union Chimique Belge (UCB), and Janssen. AYH also received honoraria from Novartis, Janssen, and Recordati. EFM has received grant or research support from AbbVie, Amgen, Biogen, AstraZeneca, Bristol Myers Squibb, Janssen, Eli Lilly, EMD Serono, Genentech, GSK, and UCB. EFM received consultant fees from EMD Serono, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Novartis, AbbVie, Galapagos, and IgM; honoraria from AstraZeneca, Biogen, Bristol Myers Squibb, EMD Serono, and Gilead; and travel support from AstraZeneca. EFM is Board Director of Rare Voices Australia, a not-for-profit organisation. MR received research grants for SLE clinical trials from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Lilly, Novartis, Pfizer, Servier, and UCB. MR received consulting fees from AbbVie, Boehringer Ingelheim, Janssen Global Services, Novartis, and Pfizer., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
150. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries.
- Author
-
Bolla E, Semb AG, Kerola AM, Ikdahl E, Petri M, Pons-Estel GJ, Karpouzas GA, Sfikakis PP, Quintana R, Misra DP, Borba EF, Garcia-de la Torre I, Popkova TV, Artim-Esen B, Troldborg A, Fragoso-Loyo H, Ajeganova S, Yazici A, Aroca-Martinez G, Direskeneli H, Ugarte-Gil MF, Mosca M, Goyal M, Svenungsson E, Macieira C, Hoi A, Lerang K, Costedoat-Chalumeau N, Tincani A, Mirrakhimov E, Acosta Colman I, Danza A, Massardo L, Blagojevic J, Yılmaz N, Tegzová D, Yavuz S, Korkmaz C, Hachulla E, Moreno Alvarez MJ, Muñoz-Louis R, Pantazis N, and Tektonidou MG
- Subjects
- Humans, Cross-Sectional Studies, Male, Female, Adult, Middle Aged, Prevalence, Risk Factors, Hypertension epidemiology, Lupus Erythematosus, Systemic epidemiology, Lupus Erythematosus, Systemic complications, Heart Disease Risk Factors, Cardiovascular Diseases epidemiology, Antiphospholipid Syndrome epidemiology, Antiphospholipid Syndrome complications
- Abstract
Background: Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus., Methods: In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process., Findings: 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33-54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome., Interpretation: High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted., Funding: None., Competing Interests: Declaration of interests AGS has received speaker fees from Merck and Schering-Plough, Bristol Myers Squibb, UCB, Pfizer, Novartis, Lilly and Women's College Hospital, Toronto, ON, Canada. AMK has received speaker fees from Boehringer Ingelheim and Sanofi; has participated on advisory boards for Pfizer, Gilead, and Boehringer Ingelheim; and has received congress sponsorship from Pfizer, Celgene, UCB, Mylan, and Roche. GJP-E has received grants from Janssen; consulting fees from GSK, AstraZeneca, Janssen, Novartis, and Bago; speakers fees from GSK, Werfen, Janssen, AstraZeneca, and Novartis; support for attending meetings and travel from GSK, AstraZeneca, and Boehringer Ingelheim; and for participation on a data safety monitoring board or advisory board from RemeGen, AstraZeneca, and Janssen. GAK has received consulting fees from Janssen and Scipher; and for participation on a data safety monitoring board or advisory board from Janssen. MFU-G has received grant support from Janssen and Pfizer; has been a speaker for GSK and AstraZeneca; and has been a member of advisory boards for AstraZeneca and Ferrer. NC-C has received grants from Roche and UCB. EH has received consulting fees and meeting fees from Johnson & Johnson, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, and Sanofi-Genzyme; speaking fees from Johnson & Johnson, GSK, and Roche-Chugai; and research funding from Commonwealth Serum Laboratories Behring, GSK, Roche-Chugai, and Johnson & Johnson. NP has received grants from Gilead Sciences Hellas and the European Centre for Disease Prevention and Control. OAM has received speaker's fees or payment for advisory boards from AbbVie, APSEN, AstraZeneca, Boehringer Ingelheim, Celltrion, GSK, and Janssen. MS has received research grants and consulting fees, and has participated as a speaker for: AbbVie, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, and AstraZeneca. ACSM has received speaker fees from GSK and AstraZeneca. All other authors and SURF-SLE and APS Collaborators declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.